MEI Pharma FY2023 net loss $31.8M; cash $100.7M; merger fails, CEO changed

Lite Strategy, Inc.

Net loss $31.8M ($4.78/share) vs $54.5M ($8.75/share) prior year; revenue $48.8M, up from $40.7M.
Cash and equivalents $100.7M, no debt; cash used in operations $52.5M.
Stockholders rejected Infinity Pharmaceuticals merger (47.86% for, 51.44% against); agreement terminated.
David M. Urso appointed CEO (June 2023); Jay File appointed CFO (effective Aug 2023).
Voruciclib+venetoclax data early 2024; ME-344+bevacizumab data H1 2024; workforce reduced 61% to 41 employees.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lite Strategy, Inc. reported financial results for fiscal year ended June 30, 2023.

Period: fiscal year ended June 30, 2023
Result: reported results

Exact text from the filing

On September 26, 2023, MEI Pharma, Inc. (the “Company”) issued a press release announcing its financial results for its fiscal year ended June 30, 2023.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Lite Strategy, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-242526

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.